Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma reported second-quarter 2026 results and progress on its pending sale to Zymeworks. Zymeworks has agreed to acquire the company for $17.00 per share in cash, plus a contingent value right (CVR) for 80% of net proceeds from any future ampreloxetine monetization over the next ten years, with closing targeted in the second half of 2026 subject to shareholder approval and customary conditions.
For the quarter ended June 30, 2026, total revenue was $20.7 million versus $26.2 million a year earlier. GAAP results showed a net loss of $5.9 million compared with net income of $54.8 million in the prior-year quarter, which had included large non-recurring gains. Non-GAAP net income was $9.5 million, improving from a non-GAAP net loss of $4.2 million. YUPELRI net sales (recorded by Viatris) were $70.7 million versus $66.3 million, implying $24.7 million for Theravance’s 35% share. Cash, cash equivalents and short-term marketable securities totaled $387.7 million at June 30, 2026. The company recorded $4.0 million of restructuring expenses and $6.1 million of transaction-related expenses in the quarter.
Theravance Biopharma, Inc. insider filings show that funds managed by Madison Avenue Partners, LP, an entity associated with reporting person Eli Samaha, executed open-market sales of common stock over three days. The funds sold 273,871 shares on June 29, 2026 at a weighted average price of about $17.23 per share, 25,027 shares on June 30, 2026 at about $17.13 per share, and 37,799 shares on July 1, 2026 at about $17.00 per share. After these transactions, the filings report that entities managed by Madison Avenue Partners, LP indirectly held 9,174,453 shares of Theravance Biopharma common stock. The footnotes state that Samaha is the managing partner of Madison Avenue Partners, LP and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Theravance Biopharma has agreed to be acquired by Zymeworks in a cash-and-CVR deal. Zymeworks will buy Theravance Biopharma for $17.00 per share in cash, valuing the company at approximately $929 million, plus a contingent value right (CVR) tied to future monetization of the drug ampreloxetine.
Each CVR gives holders 80% of net proceeds from any license, divestiture or other monetization of ampreloxetine over ten years, plus a share of specified milestone and royalty payments as described in the CVR agreement. The price represents a 22% premium to the March 3, 2026 closing price and a 10% premium to the volume-weighted average price since that date. Closing is targeted for the second half of 2026, subject to shareholder approval, antitrust clearance and other customary conditions.
Miller Aine reported acquisition or exercise transactions in this Form 4 filing.
Theravance Biopharma, Inc. reported that senior vice president Aine Miller received a grant of 18,750 Ordinary Shares on June 19, 2026. The award was recorded at a price of $0.0000 per share, reflecting a compensation-related grant rather than a market purchase. Following this transaction, Miller directly holds 196,084 Ordinary Shares of Theravance Biopharma.
Theravance Biopharma, Inc. disclosed that its subsidiary Theravance Biopharma Ireland Limited entered into a compromise agreement with Dr. Áine Miller, Senior Vice President, Development and Head of the Ireland office. Under this agreement, her employment will terminate on November 15, 2026 as part of the restructuring announced in March 2026.
The agreement follows the terms of her existing employment contract, as amended in February 2026. The company will also make a $250,000 special pension contribution for Dr. Miller within 30 days after the termination date. In addition, on June 19, 2026, she received a grant of 18,750 restricted share units in connection with her continued service through the termination date.
Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported selling ordinary shares in open-market transactions. On June 15, 2026, she sold a total of 13,314 ordinary shares of Theravance Biopharma in three separate trades.
The reported sale prices were around the mid‑$16 range per share, with individual weighted-average prices of $16.3856, $16.3838 and $16.3902. A footnote explains that these transactions were executed in multiple trades between $16.21 and $16.61 per share, and the prices disclosed reflect the weighted-average sale prices across those trades.
Theravance Biopharma director Laurie Smaldone Alsup received new equity compensation in the form of shares and options. On 2026-06-12, she was granted 6,009 Ordinary Shares at no cost, increasing her direct holdings to 80,989 shares.
On the same date, she was also granted a Share Option covering 13,398 Ordinary Shares at an exercise price of $16.6400 per share, expiring on 2036-06-11. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant date, with any remaining unvested portion vesting on the date of the next annual shareholder meeting, subject to continued service.
Theravance Biopharma director Susannah Gray received equity compensation in the form of shares and options. On June 12, 2026, she was granted 6,009 Ordinary Shares, bringing her direct holdings to 48,146 Ordinary Shares after the award.
On the same date, she also received a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each completed month of continuous service following the grant date, and any remaining unvested portion vests on the date of the next annual shareholder meeting if she remains in continuous service.
Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares. The options have an exercise price of $16.64 per share and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues.
Theravance Biopharma director Donal O'Connor received new equity awards. On June 12, 2026, he was granted 6,009 Ordinary Shares at no cost, increasing his direct holdings to 80,213 Ordinary Shares.
He was also granted a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option shares vest after each continuous month of service following the grant date, with any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided he remains in continuous service.